Literature DB >> 21173543

High COPD prevalence in patients with liver disease.

Yoshiaki Minakata1, Hiroki Ueda, Keiichiro Akamatsu, Masae Kanda, Satoru Yanagisawa, Tomohiro Ichikawa, Akira Koarai, Tsunahiko Hirano, Hisatoshi Sugiura, Kazuto Matsunaga, Masakazu Ichinose.   

Abstract

OBJECTIVE: Comorbidities of chronic obstructive pulmonary disease (COPD) have been recognized as an important issue in COPD management. We have reported that patients with liver diseases show a higher prevalence of COPD, but the number of patients with liver diseases was small and the details of liver diseases were not clearly investigated. In this study, we investigated the prevalence of COPD in patients with liver diseases by recruiting a large number of patients, and also investigated was the effect of hepatitis virus infection on COPD prevalence. PATIENTS AND METHODS: Six hundred sixty-six patients were recruited from 9 primary care clinics and three hospitals. All of these patients were aged 40 years or older with chronic diseases and had not been diagnosed as having respiratory diseases. A spirometry was performed without administration of an inhaled bronchodilator. Airflow limitation was defined as FEV1/FVC<70%. Underlying diseases were diagnosed by doctors of the clinics or the hospitals.
RESULTS: Two hundred fifty-six patients had liver diseases, and 410 did not. Of 410 patients without liver diseases, 37 patients (9.0%) were diagnosed as COPD, and of 256 patients with liver diseases, 35 patients (13.8%) were COPD. When the prevalence was analyzed according to smoking, age and gender, liver diseases showed a significantly high odds ratio (2.10, 95%CI 1.23-3.57, p=0.006), but hepatitis virus infection showed a non-significant tendency toward a high odds ratio.
CONCLUSION: The patients with liver diseases had a significantly high prevalence of COPD. The presence of liver disease might become a useful predictor for the early detection of COPD.

Entities:  

Mesh:

Year:  2010        PMID: 21173543     DOI: 10.2169/internalmedicine.49.3948

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  9 in total

Review 1.  The influence of virus infections on the course of COPD.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Sarcopenia Is an Independent Risk Factor for NAFLD in COPD: A Nationwide Survey (KNHANES 2008-2011).

Authors:  Kyung Soo Hong; Min Cheol Kim; June Hong Ahn
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-05-07

3.  Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010.

Authors:  Sung Woo Moon; Song Yee Kim; Ji Ye Jung; Young Ae Kang; Moo Suk Park; Young Sam Kim; Joon Chang; Jun Soo Ro; Yong-Ho Lee; Sang Hoon Lee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-08-28

4.  MAFLD associated with COPD via systemic inflammation independent of aging and smoking in men.

Authors:  Tsubasa Tsutsumi; Dan Nakano; Machiko Kawaguchi; Ryuki Hashida; Shinobu Yoshinaga; Hirokazu Takahashi; Keizo Anzai; Takumi Kawaguchi
Journal:  Diabetol Metab Syndr       Date:  2022-08-16       Impact factor: 5.395

Review 5.  The Emerging Clinical Significance of the Red Cell Distribution Width as a Biomarker in Chronic Obstructive Pulmonary Disease: A Systematic Review.

Authors:  Angelo Zinellu; Arduino A Mangoni
Journal:  J Clin Med       Date:  2022-09-25       Impact factor: 4.964

6.  Low alanine aminotransferase as a risk factor for chronic obstructive pulmonary disease in males.

Authors:  Yong Jun Choi; Do Sun Kwon; Taehee Kim; Jae Hwa Cho; Hyung Jung Kim; Min Kwang Byun; Hye Jung Park
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

7.  Comorbidity in patients with chronic obstructive pulmonary disease in family practice: a cross sectional study.

Authors:  Luis García-Olmos; Angel Alberquilla; Victoria Ayala; Pilar García-Sagredo; Leticia Morales; Montserrat Carmona; María José de Tena-Dávila; Mario Pascual; Adolfo Muñoz; Carlos H Salvador; Jose L Monteagudo
Journal:  BMC Fam Pract       Date:  2013-01-16       Impact factor: 2.497

8.  Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD.

Authors:  Douglas W Mapel; Jenõ P Marton
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-03-15

9.  Low serum levels of alpha1 anti-trypsin (α1-AT) and risk of airflow obstruction in non-primary α1-AT-deficient patients with compensated chronic liver disease.

Authors:  Elizabeth Rodríguez-Romero; Juan Antonio Suárez-Cuenca; César Iván Elizalde-Barrera; Paul Mondragón-Terán; José Enrique Martínez-Hernández; Eduardo Gómez-Cortés; Rebeca Pérez-Cabeza de Vaca; Rolando E Hernández-Muñoz; Alberto Melchor-López; Nayeli Gabriela Jiménez-Saab
Journal:  Med Sci Monit       Date:  2015-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.